Psyence Biomedical Ltd.
42.9M
$0.11M
14.15
$1.78
No price alerts set. Add an alert to get notified!
14.15
2.13
$1.78
15.05%
0.00%
0.00%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
AZTR
Azitra, Inc.
|
$0.22 | -0.61% | -0.10 | $2.35M | 0.16 |
|
DRMA
Dermata Therapeutics, Inc.
|
$1.35 | 7.14% | -0.22 | $920,102 | 0.00 |
|
ELAB
PMGC Holdings Inc.
|
$3.81 | -9.29% | -0.01 | $7.38M | 0.34 |
|
GTBP
GT Biopharma, Inc.
|
$0.40 | 2.81% | -0.08 | $4.24M | 0.00 |
|
INDP
Indaptus Therapeutics, Inc.
|
$3.04 | 12.18% | -0.32 | $5.32M | 0.00 |
|
LIPO
Lipella Pharmaceuticals Inc.
|
$0.02 | -34.33% | -0.02 | $91,030 | 0.18 |
|
NKGN
NKGen Biotech, Inc. Common Stock
|
$0.07 | 16.67% | -0.14 | $9.14M | -0.76 |
|
PTIX
Protagenic Therapeutics, Inc.
|
$0.54 | -1.82% | -0.20 | $1.04M | -1.32 |
|
REVB
Revelation Biosciences, Inc.
|
$1.20 | -4.76% | -0.08 | $4.46M | 0.08 |
|
SPRC
SciSparc Ltd.
|
$4.32 | 27.43% | -0.02 | $249,864 | -3.14 |
* Peer stocks are selected based on market capitalization and sector
$468.36
$1.92
$0.00
0.00%
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
